Development of a Cascade-Targeting Oral Vaccine via Glycoprotein 2 on Intestinal Microfold Cells for Cancer Immunotherapy

T cells. More importantly, this oral vaccine can evoke not only cellular but also humoral and mucosal immune responses. Therefore, this cascade-targeting oral vaccine could serve as a novel platform for cancer immunotherapy and infectious disease prevention as well.